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Abstract
Rationale—The endogenous cannabinoid (CB) system mediates a number of behaviors 
associated with drug-seeking and drug self-administration. In this study the effects of CB1 
receptor manipulations on operant ethanol (EtOH) responding during EtOH-seeking, EtOH- 
relapse as well as on-going EtOH self-administration were determined.
Methods—Alcohol-preferring (P) rats were trained in 2-lever operant chambers to self-
administer 15% EtOH (v/v) and water on a concurrent fixed-ratio 5 – fixed-ratio 1 (FR5-FR1) 
schedule of reinforcement in daily 1-hr sessions. After 10 weeks, rats underwent 7 extinction 
sessions, followed by 2 weeks in their home cages without access to EtOH or operant chambers. 
Rats were then returned to the operant chambers for testing of EtOH-seeking behavior (no EtOH 
present) for 4 sessions. After a week in their home cages following the EtOH-seeking test, rats 
were returned to the operant chambers with access to EtOH and water (relapse). Rats were then 
maintained in the operant chambers for daily 1-hr sessions with access to 15% EtOH and water for 
several weeks.
Results—The CB1 receptor antagonist (SR141716A), at doses of 1 and 2 mg/kg, i.p. reduced 
EtOH-seeking and transiently reduced EtOH self-administration during relapse and maintenance. 
Conversely, treatment with the CB1 receptor agonist CP, 55-940, at doses of 1 and 10 μg/kg i.p., 
increased EtOH-seeking and EtOH self-administration during relapse.
Conclusions—The results of this study demonstrate that activation of CB1 receptors are 
involved in regulating EtOH-seeking as well as the reinforcing effects of EtOH under relapse and 
on-going self-administration conditions.
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1. INTRODUCTION
Epidemiological data indicates that 58% of subjects who abuse ethanol (EtOH) or are 
alcohol dependent also abuse marijuana (Martin et al., 1996). EtOH and Δ9 
tetrahydrocannabinol (THC), the main psychoactive constituent of marijuana, activate 
similar reward pathways (Gessa et al., 1998). There also exists cross-tolerance between 
EtOH and THC suggestive of the involvement of possible common pathway(s) 
(Basavarajappa and Hungund, 2002). One of the systems that is activated by both EtOH and 
CBs/THC is the endogenous cannabiniod (CB) system. The CB system plays an important 
role in homeostatic control of emotions and regulation of motivated behavior (Navarro et al., 
2001), and the pharmacological and behavioral effects of alcohol (Hugund & Basavarajappa, 
2000; Gonzalez et al., 2002; Hungund et al., 2002 and Colombo et al., 2005). For instance, 
chronic (Ortiz et al 2004), as well as intermittent EtOH (Rimondini et al., 2002) results in 
alterations of the CB1receptor: i.e., gene expression, receptor binding (Basavarajappa et al., 
1998), and function (Basavarajappa and Hungund, 1999).
CB1 agents manipulate different aspects of EtOH related behaviors, such as EtOH modulate 
CB system in different animal models and experimental designs. Microinjections of the CB1 
antagonist, SR141716 (SR) into the nucleus accumbens (NAcc) and ventral tegmental area 
(VTA) attenuates EtOH responding in Alko Alcohol (AA) rats (Malinen and Hyytiä, 2008). 
The modulation of alcohol reward by the CB system previously has been shown to be via 
the NAcc (Caille et al., 2007) and the prefrontal cortex (Hansson et al., 2007). Recently, it 
was reported significant dose-dependent reduction in EtOH intake following SR141716A 
administration into the posterior, but not anterior VTA, consistent with evidence of a 
specific involvement of the posterior VTA in the regulation of EtOH intake (Alvarez-
Jaimes, et al 2009).
Systemic administration of SR, suppresses acquisition and maintenance as well as relapse 
drinking in selectively bred Sardinian EtOH-preferring (sP) rats (Colombo et al., 1998; Serra 
et al., 2001; 2002). Further, SR treatment of EtOH-consuming C57BL/6 mice (Arnone et al., 
1997) and chronically EtOH-exposed Wistar rats (Lallemand et al., 2001) also reduces 
drinking. Similar results were reported in unselected Long Evans and Wistar rats (Freedland 
et al., 2001; Hungund et al., 2002; Cippitelli et al., 2005; Economidou et al., 2006). CB1 
receptor knockout mice that lack CB1 receptors display significantly lower levels of EtOH-
preference and consumption compared to the wild-type mice (Hungund et al., 2003; 
Poncelet et al., 2003; Wang et al., 2003 and Naassila et al., 2004).
Administration of the CB1 receptor agonist, CP 55,940 (CP), promotes EtOH-intake 
(Gallate et al., 1999; Colombo et al., 2002); chronic exposure to a CB1 agonist potentiates 
operant self-administration of EtOH and relapse drinking (Lopez-Moreno et al., 2005). 
Further, CP stimulates the activity of mesolimbic dopaminergic (DA) neurons and enhances 
brain stimulation-induced reward (Gardner and Vorel, 1998). CB1 receptor knockout mice 
lack EtOH-induced DA release in the NAcc (Hungund et al., 2003). Taken together, the data 
from SR, CP as well as knockout mice studies suggest a role for CB system in EtOH-related 
behaviors.
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However, to date, few studies have been carried out in animals that display robust EtOH-
seeking and- relapse drinking. Alcohol-preferring (P) rats do display long and robust relapse 
drinking; the temporary increase in EtOH intake observed with P rats under relapse 
conditions is indicative of alcohol deprivation effect (ADE). Although, AA rats display 
increased EtOH intake during the first hour after a few hours of EtOH deprivation (Sinclair 
and Li, 2003), however, longer deprivation produces progressively smaller first-hour intakes 
in the AAs (Sinclair and. Tiihonen, 1989). In the case of sP rats, the ADE is limited to the 
first hour of each repeated access period and magnitude of this ADE did not increase with 
repeated deprivation (Serra et al., 2003). By comparison the P rats exhibit both “long and 
short ADE” (Sinclair and Li, 1989, Vengeliene et al., 2003).
In addition, P rats exhibit significant Pavlovian Spontaneous Recovery (PSR), which is an 
index of seeking behavior. PSR is reinstatement of responding (goal seeking) or a 
conditional response, in the absence of the previously trained reward following a period of 
rest after extinction (Pavlov, 1927). The application of the PSR phenomenon to animal 
studies of alcohol abuse has a number of beneficial aspects. First, spontaneous responding 
procedures assess operant behavior in the absence of passive drug administration within the 
environment previously associated with drug availability. Therefore, all responses are 
thought to be intrinsically motivated (Pavlov, 1927) and are not the result of drug-induced 
actions. Thus, spontaneous responding can be conceived as a suitable paradigm to assess 
‘drug-craving’ or ‘drug-seeking’ in animals. This persistence of responding in the absence of 
reward parallels the compulsive nature of drug abuse in humans (Anton, 1999). Thus, P rat 
are unique in its predisposition to expressing pronounced EtOH craving/relapse, and that the 
PSR procedure may be a potentially valid and important measure for studying EtOH-craving 
behavior. Therefore, use of P rats, implementation of PSR and ADE paradigms to examine 
seeking relapse and relapse drinking provides a unique experimental model to study 
pharmacological effects on these EtOH-related behaviors in animals.
The goal of the present study was to assess the effects of CB1 receptor antagonist 
(SR141716A) and agonist (CP 55,940) on operant EtOH-responding of female P rats under 
EtOH-seeking, -relapse, and on-going self-administration conditions. The overall hypothesis 
to be tested is that CB1 receptors are involved in regulating of EtOH-seeking, relapse and 
on-going drinking. The CB1 antagonist would reduce EtOH-seeking, relapse and on-going 
drinking whereas the CB1agonist would enhance these behaviors.
2. MATERIALS AND METHODS
2.1. Animals
Adult female P rats weighing 250–325g at the start of the experiment were used. Rats were 
maintained on a 12-hr reversed light-dark cycle (lights off at 0900 hr). Food and water were 
available ad libitum throughout the experiment, except during operant testing. The animals 
used in these experiments were maintained in facilities fully accredited by the Association 
for the Assessment and Accreditation of Laboratory Animal Care (AAALAC). All research 
protocols were approved by the institutional animal care and use committee and are in 
accordance with the guidelines of the Institutional Care and Use Committee of the National 
Institute on Drug Abuse, National Institutes of Health, and the Guide for the Care and Use 
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of Laboratory Animals (Institute of Laboratory Animal Resources, Commission on Life 
Sciences, National Research Council 1996).
2.2.1. Operant Apparatus—Experiments were conducted in standard two-lever operant 
chambers (Coulbourn Instruments, Whitehall, PA) contained within ventilated, sound-
attenuated enclosures. Two operant levers were located on the same wall and were placed 15 
cm above a grid floor and 13 cm apart. Directly beneath each lever was a trough through 
which a dipper cup (0.1 ml) was raised to deliver response-contingent fluid. Upon a 
reinforced response, a small light cue was illuminated in the drinking trough during the 4-
sec dipper cup access. A computer controlled all operant chamber functions and recorded 
lever responses and dipper presentations. Operant sessions were 60 min in duration and were 
conducted daily.
2.2.2. Operant Training—Without any prior training, exposure to the experimental set-
up, or access to EtOH, rats were placed in the operant chambers. Both the EtOH (15% v/v) 
and water levers were maintained on a fixed-ratio 1 (FR1) schedule of reinforcement for the 
first 5 weeks. Subsequently, the reinforcement schedule on the EtOH lever was increased to 
FR3 in weeks 6 –7, and to FR5 in weeks 8–10. The FR requirement for EtOH was increased 
to ensure a high baseline level of responding. The FR1 schedule was maintained for water 
because increasing the requirement would result in a further reduction in the low level of 
responding on this lever. Responses on the water lever during the PSR and relapse test 
sessions served to evaluate non-specific effects of CB1 agents on motor systems. The 
number of responses on the EtOH and water lever and the number of EtOH and water 
reinforcements were recorded throughout each session. Levers associated with EtOH or 
water were counterbalanced among rats but remained constant for each animal.
2.2.3. Extinction—After 4 weeks of responding on the FR5 schedule for EtOH and FR1 
for water, rats underwent extinction. The lever previously associated with the delivery of 
EtOH was maintained on a FR5 schedule, and the lever previously associated with the 
delivery of water was maintained on an FR1. With the exception of no fluid being presented, 
the delivery system operated exactly as the preceding EtOH self-administration sessions; 
rats still received the auditory stimulus of the dipper raising and the visual cue of the small 
light being illuminated above the dipper trough. Rats were exposed to 7 consecutive 
extinction sessions which has been previously been shown to extinguish the EtOH response 
(Rodd-Henricks et al., 2002).
2.2.4. Pavlovian Spontaneous Recovery (PSR) testing—After extinction training, 
all rats were maintained in their home cages for 14 days, without access to EtOH or operant 
chambers. Following this home cage period, rats were returned to the operant chambers 
without EtOH or water. Lever contingencies and dipper functioning were maintained, as 
described for operant self-administration and extinction training. Rats were given 4 
consecutive PSR test sessions, as previously described (Rodd-Henricks et al., 2002).
2.2.5. Relapse—Following the PSR phase of the experiment, all rats were maintained in 
the home cages for 7 days. Rats were then transferred to the operant chambers with both 
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15% EtOH and water available for the 60-min sessions. The EtOH lever was maintained on 
a FR5 schedule and the water lever on a FR1 schedule.
2.2.6. Maintenance—Following the relapse phase, rats received daily EtOH operant 
sessions for 3–4 weeks on the concurrent FR5-FR1 schedule of reinforcement. During 
maintenance sessions both 15% EtOH and water were available.
2.3. Effects of CB1 Antagonist SR141716A on PSR, Relapse, and Maintenance
SR141716A (SR, was provided by NIDA, Washington DC, USA). SR was suspended in 1 
ml/kg saline with 0.1% Tween 80. The doses of SR were 0, 0.3, 1 and 2 mg/kg. The typical 
log dose of 3 mg/kg was not used because of uncertainty of a constant dispersion of SR in 
the suspension at this concentration. Following extinction training, adult female P rats (n = 
36) were randomly assigned to one of four groups, which received a single i.p. injection of 
0, 0.3, 1 or 2 mg/kg SR (n = 8–10/group) 15 minutes prior to the first PSR test session only. 
Rats were not injected prior to the subsequent 3 PSR test sessions.
These same rats were also used to test the effects of SR during relapse and maintenance 
responding, using a counterbalanced design (i.e., rats that were administered 1 mg/kg SR 
during the PSR test sessions were randomly assigned to separate groups that received one of 
the 4 doses of SR during the relapse phase, which were then counterbalanced for 
maintenance). Eight rats were removed prior to maintenance testing (thus n = 28 for 
maintenance testing) because of another planned study. For relapse testing, rats received 0, 
0.3, 1 or 2 mg/kg SR (n = 8–10/group) 15 min prior to each of the first 4 relapse sessions. 
Following relapse testing, rats were maintained on the 1-hr operant sessions with access to 
EtOH and water for 25 days; they were then assigned to groups to receive i.p injection of 0, 
0.3, 1 or 2 mg/kg SR (n = 6–8/group) 15 min prior to four consecutive operant sessions.
2.4. Effects CB1 Agonist CP-55,940 on PSR and Relapse
CP-55,940 (CP; Tocris, Bristol, UK) was suspended in 1 ml/kg saline with 0.1% Tween 80. 
Following extinction training, the effects of CP on lever responses in the PSR test was 
examined in adult female (n = 23) P rats. P rats received an i.p. injection of 0, 1, 10, or 30 
μg/kg CP (n = 5–6/group) 15 minutes prior to the first PSR test session. Rats were not 
injected prior to the subsequent 3 PSR test sessions. The same P rats were used to test the 
effects of CP during relapse responding, using a counterbalanced design (i.e., rats that were 
administered 30 μg/kg CP during the PSR test sessions were randomly assigned to separate 
groups that received one of the 4 doses of CP during the relapse testing. For relapse testing, 
rats received 0, 1, 10, or 30 μg/kg CP (n = 5–6/group) 15 min prior to each of the first 4 
reinstatement sessions.
2.5. Statistical Analyses
Overall operant responding (60-min) data were analyzed with a mixed factorial ANOVA 
with a between subject factor of dose and a repeated measure of ‘session’. For the PSR 
experiments, the baseline measure for the factor of ‘session’ was the average number of 
responses on the EtOH lever for the last 3 extinction sessions. For the relapse studies, the 
baseline measure for the factor of ‘session’ was the average number of responses on the 
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EtOH lever for the 3 sessions immediately prior to extinction. Baseline values for the 
maintenance experiment were the 3 sessions immediately prior to testing the CB1 
compounds. Post-hoc Tukey’s b tests were performed to determine individual differences.
3. RESULTS
3.1. Effects of the CB1 Antagonist SR141716A on PSR, Relapse, and Maintenance
3.1.1. PSR—In all groups, there was significant alteration in responding during the initial 
PSR session compared to extinction baseline (p values < 0.05). Individual ANOVAs 
performed on each PSR test session indicated that only during the first PSR test session was 
there a significant effect of ‘dose’ (F3,32 = 22.14; p < 0.001). Post-hoc comparisons 
(Tukey’s b) indicated that responses by rats treated with vehicle were significantly higher 
than responding by all other groups, and responses by rats treated with 0.3 mg/kg SR were 
significantly higher than P rats treated with 1 or 2 mg/kg SR (which did not differ from each 
other). Performing t-tests within each group contrasting the average number of responses 
performed during the last three days of extinction with the number observed during the 1st 
PSR test session indicated that P rats treated with saline or 0.3 mg/kg SR had higher EtOH 
lever responses (p values < 0.05). In contrast, administration of 1 or 2 mg/kg SR had lower 
EtOH responses during the 1st PSR test session compared to the level observed during the 
last three extinction sessions (p values < 0.01). Water responding (data not shown) was 
generally low throughout the experiment, and did not alter from values observed prior to 
extinction (23.4 ± 2.4 responses/session), during extinction (19.6 ± 3.2 responses/session), 
or during the 1st PSR test session (16.8 ± 5.8 responses/session). Statistically, there was no 
effect on water responding; ‘session’ (F4,29 = 0.2; p = 0.89), dose (F3,32 = 2.4; p = 0.13), 
‘session’ by ‘dose’ interaction (F12,93 = 1.3; p = 0.23).
3.1.2. Relapse—During relapse testing, injections of the 2 highest doses of the CB1 
receptor antagonist reduced EtOH responding (Fig. 2). There were no significant carry-over 
effects of treatment with SR during PSR testing (all p values > 0.05). Therefore, PSR doses 
were not included as factors in the relapse statistical analysis. During the 1st through 4th 
relapse session, post-hoc comparisons indicated that P rats treated with vehicle and 0.3 
mg/kg SR were significantly higher than P rats treated with 1 or 2 mg/kg SR. In P rats 
treated with 1 mg/kg SR, responding for EtOH was reduced for the 1st and 2nd relapse 
sessions compared to baseline (p values < 0.05). In P rats treated with 2 mg/kg SR, 
responding for EtOH was reduced during the 1st, 2nd, and 3rd relapse session (p < 0.05). 
Water responding (data not shown) was not altered between pre-extinction levels and the 
amount of responding observed during the 1st – 7th relapse sessions (average water 
responses/session 25.7 ± 3.8; all p values > 0.05).
3.1.3. Maintenance—During maintenance testing, injections of the 2 highest doses of 
CB1 antagonist reduced EtOH responding (Fig. 3). There were no significant carry-over 
effects of treatment with on maintenance testing (all p values > 0.05). The overall analysis 
indicated a significant effect of ‘session’ (F8,25 = 32.5; p < 0.001) and a ‘session’ by ‘dose’ 
interaction (F24,81 = 2.5; p = 0.01). There was a significant effect of ‘dose’ for the 4 sessions 
that SR was administered prior to each test session (F3,32 values > 3.6; p values < 0.023). 
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During the initial maintenance session, post-hoc comparisons indicated that P rats treated 
with vehicle and 0.3 mg/kg SR responded significantly more than P rats treated with 1 or 2 
mg/kg SR. During the subsequent injection sessions, P rats treated with the 1 and 2 mg/kg 
doses began to recover toward baseline. Vehicle treated rats had a small decrease in 
responding compared to baseline responding during the 1st maintenance session, but the 
decrease was not statistically significant. In P rats treated with 1 or 2 mg/kg SR, responding 
during the 1st maintenance session was reduced compared to baseline responding (p values < 
0.001). Responding during injection sessions 2–4 increased significantly compared to the 1st 
injection session (F values 3,21 > 6.5; p values < 0.01). Similar to results for relapse 
responding, responding began to recover toward baseline in the 1 and 2 mg/kg group in 
sessions 2–4. Water responding (data not shown) was consistent during maintenance in all 
groups (average water responses/session 21.8 ± 5.3; all p values > 0.05).
3.2. Effects of CB1 Agonist CP-55,940 (CP) on PSR and Relapse
3.2.1. PSR—In PSR test, the CB1 receptor agonist had a biphasic effect on responding on 
the EtOH lever, with the 2 lowest doses increasing responding and highest dose reducing 
responding compared to vehicle control values (Fig. 4). In all groups, except the 30 μg/kg 
CP group (p = 0.38) there was significant increase in responding on the EtOH lever during 
the initial PSR session compared to extinction baseline (p values < 0.05). Individual 
ANOVAs performed on each PSR test session indicated that only during the first PSR test 
session was there a significant effect of ‘dose’ (F3,19 = 4.8; p = 0.012). Post-hoc 
comparisons (Tukey’s b) indicated that there were significant differences between all groups 
in female P rats responding on the lever previously associated with the delivery of EtOH. P 
rats treated with the highest dose of CP (30 μg/kg) responded less than vehicle treated rats, 
whereas P rats treated with the low doses of CP (1 and 10 μg/kg) responded more than the 
vehicle group. P rats treated with vehicle or 1 and 10 μg/kg CP prior to the 1st PSR session, 
responded more on the lever previously associated with the delivery of EtOH than 
performed during extinction training (p values < 0.0001). The 30 μg/kg CP group 1st PSR 
session responding was not significantly different from extinction baseline responding. The 
significant effect of session was the result of a small increase in water responding during the 
3rd and 4th (22 ± 3) PSR test session compared to extinction responding (16 ± 2), whereas no 
effect on water lever responding was observed during PSR sessions 1 and 2.
3.2.2. Relapse—P rats treated with saline increased EtOH responding during the 1st 
relapse session compared to baseline levels (Fig. 5). Rats administered low doses of CP (1 
and 10 μg/kg) responded more compared to baseline during the initial 2 relapse sessions. In 
contrast, the 30μg/kg dose of CP reduced EtOH responding during all 4 relapse sessions. 
Individual ANOVAs performed on each of the four relapse sessions indicated that only 
during the first two reinstatement sessions was a significant effect of ‘dose’ (p values = 
0.008). Post-hoc comparisons (Tukey’s b) indicated that there were significant differences 
between all groups of P rats responding on the EtOH lever during the 1st and 2nd 
reinstatement session. P rats treated with the highest dose of CP (30 μg/kg) responded less 
than vehicle treated rats, whereas P rats treated with the low doses of CP (1 and 10 μg/kg) 
responded more than vehicle group. During the 3rd and 4th relapse sessions, post-hoc 
comparisons indicated that the highest dose of CP reduced responding compared to all other 
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groups, whereas the 1 and 10 μg/kg doses were no longer effective. Water responding was 
low (~15 responses/session) and was not significantly altered by any of the treatments (P 
values >0.05).
4. DISCUSSION
The major findings of the current study are that 1 and 2 mg/kg of the CB1 antagonist, 
SR-141716A (SR), suppressed seeking and transiently reduced EtOH self-administration 
during relapse and maintenance; whereas, CB1 agonist, CP 55, 940 (CP) at doses of 1 and 
10 μg/kg increased seeking and relapse of EtOH in female P rats. These results suggest that 
activation of CB1 receptors is involved in regulation of seeking, relapse and maintenance of 
alcohol self-administration. This is in agreement with previous reports (Gallate et al., 1999; 
Hugund & Basavarajappa, 2000; Colombo et al., 2002, 2004; Gonzalez et al., 2002; 
Hungund & et al., 2002; Malinen and Hyytiä, 2008) that showed the CB1 receptor system 
plays a role in the regulation of alcohol preference, consumption and mediation of alcohol 
reinforcing and motivational properties.
The high responding on the EtOH lever during the PSR test (Figs. 1 and 4) suggests that P 
rats are expressing robust EtOH-seeking behavior. These results are consistent with 
previously published findings (Rodd-Henricks et al., 2002). Systemic administration of the 
SR compound (Fig. 1) reduced responding on the EtOH lever at all 3 doses, whereas the two 
lowest doses of the CB1 agonist increased responding on the EtOH lever during the PSR test 
(Fig. 4). The reduction in responding by the SR compound does not appear to be due to a 
motor impairing effect since responses on the water lever were not altered at any dose. 
Likewise, the increased responding on the EtOH lever during the PSR test by the two lowest 
doses of the CP compound does not appear to be due to a general increase in motor activity 
since responding on the water lever was not significantly altered. Therefore, the results 
suggest that the CB1 receptor system may be activated during EtOH-seeking behavior. If 
EtOH-seeking responding reflects craving-like behavior, these results suggest that marijuana 
smoking could promote alcohol drinking. The results with the CB1 antagonist observed in 
the present study are in agreement with the findings of Cippitelli et al. (2005), which 
indicated that administration of SR141716 reduced cue-induced responding in a conditioned 
reinstatement of EtOH-seeking behavior in non-selected Wistar rats, as well as in 
Marchigian Sardinian alcohol-preferring (msP) rats.
In support of the interpretation that activation of the CB1 receptor system is involved in 
regulating EtOH-seeking behavior are the findings with the CB1 agonist (Fig. 4). The two 
lowest doses of the CB1 agonist markedly increased responding on the EtOH lever (without 
altering responses on the water lever) suggesting that further increasing the activation of 
CB1 receptors enhances EtOH-seeking behavior. On the other hand, the higher dose of the 
CB1 agonist (30 ug/kg) reduced responding on the EtOH lever in the PSR test (Fig. 4), 
suggesting that this dose may be having a secondary effect to inhibit EtOH-seeking behavior 
or prevent expression of EtOH-seeking behavior in the PSR test.
Similar to the effects observed in the PSR test, systemic administration of the SR compound 
reduced responding, whereas the CB1 agonist (at the two lowest doses) increased 
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responding on the EtOH lever under relapse alcohol drinking conditions (Figs. 2 and 5). 
These results suggest that activation of the CB1 receptor is also involved in regulating 
alcohol drinking under relapse conditions. Furthermore, these results suggest that exposure 
to cannabinoids can promote relapse drinking during periods of abstinence, and support an 
argument that marijuana smoking could have a negative influence on individuals who are 
undergoing treatment to reduce their alcohol drinking behavior. The present results are in 
agreement with the findings of Gessa et al. (2005), who reported that administration of the 
CB1 antagonist reduced relapse drinking in sP rats, and the results of Lopez-Moreno et al. 
(2004), who demonstrated that a CB1 agonist increased EtOH drinking under relapse 
conditions.
The CB1 antagonist, at the two highest doses, reduced responding on the EtOH lever under 
maintenance conditions (Fig. 3). These results are compatible with the findings by Gallate et 
al. (1999) and Colombo et al. (2002), who reported that CB1 agonists increased EtOH intake 
of Wistar and sP rats, respectively. In addition, the present results (Fig. 3) are also in 
agreement with the findings that systemic administration of the SR compound reduced 
acquisition and maintenance of EtOH drinking in sP rats (Colombo et al., 1998; Serra et al., 
2001, 2002).
With repeated administration, there was a progressive loss of the effectiveness of the SR 
compound to reduce responding on the EtOH lever during maintenance (Fig. 3) or relapse 
(Fig. 2). Similarly, the effectiveness of the two lowest doses of the CB1 agonist to increase 
responding was also diminished with repeated administrations (Fig. 5). The loss of 
effectiveness with repeated treatments could be due to a combination of factors, including 
increased metabolism or clearance of the SR or CP compound, alterations in the affinity or 
number of CB1 receptors, and/or internalization of the CB1 receptors.
At the highest dose of the CB1 agonist, there was decreased responding on the EtOH lever 
compared to control values (Figs. 4 & 5). At the higher dose, the CP compound may be 
acting at other receptors (Ross, 2003; Herkenham et al., 1991; Devane et al., 1988). The 
action at other receptors may counter the low-dose stimulating effects and/or produce motor 
impairment to prevent responding (Romero et al., 2002; Fan et al., 1996).
These results suggest that activation of the CB1 receptor is involved in regulating EtOH-
seeking, -relapse and –maintenance behaviors, and further support the idea that marijuana 
smoking could have a significant impact on promoting alcohol drinking behavior. In 
conclusion, administration of the CB1 receptor antagonist, SR, reduced EtOH-seeking and 
transiently reduced EtOH self-administration during relapse and maintenance conditions. 
Conversely, treatment with the CB1 receptor agonist CP increased EtOH-seeking and EtOH 
self-administration during relapse and maintenance conditions. Therefore, compounds that 
modulate cannabinoid receptors are good targets for the development of drugs that could be 
useful in the treatment of alcoholism particularly in alcoholics that also smoke marijuana.
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Fig. 1. 
Depicts the Mean (± SEM) responses/session on the lever previously associated with the 
delivery of EtOH in female P rats (n = 8–10/group) given 0, 0.3, 1, or 2 mg/kg SR 141716, 
15 min prior to 1st PSR session. * Indicates that vehicle and 0.3 mg/kg groups responded 
significantly more (p<0.05) on the EtOH lever during the 1st PSR session compared to 
baseline levels, and all other groups were different compared to extinction baseline 
(F3,32)=22.4, p<0.001).
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Fig. 2. 
Depicts the Mean (± SEM) responses/session on the EtOH lever in female P rats (n = 8–10/
group) given 0, 0.3, 1, or 2 mg/kg SR141716 15 min prior to 4 operant reinstatement 
sessions (ADE). * Indicates that vehicle and 0.3 mg/kg groups were significantly different 
from the 1 and 2 mg/kg groups.
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Fig. 3. 
Depicts the Mean (± SEM) responses/session on the EtOH lever by female P rats (n = 8–10/
group) given 0, 0.3, 1, or 2 mg/kg SR141716, 15 min prior to the initial four sessions 
(maintenance). * Indicates that vehicle and 0.3 mg/kg groups were significantly different 
from the 1and 2 mg/kg groups. +Indicates that vehicle and 0.3 mg/kg rats were significantly 
different from the 1 and 2 mg/kg groups, which were different from each other. # Indicates 
that vehicle and 0.3 mg/kg groups were different from the 2 mg/kg group.
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Fig. 4. 
Depicts the Mean (± SEM) responses/session on the lever previously associated with the 
delivery of EtOH in female P rats (n = 5–6 group) given 0, 1, 10, or 30 μg/kg CP 55,940 15 
min prior to the 1st PSR session. + Indicates that vehicle, 1 or 10 μg/kg CP groups responded 
significantly (p < 0.05) more on the EtOH lever during the 1st PSR session compared to 
baseline levels and 1 or 10 μg/kg CP groups responded more than vehicle treated group.
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Fig. 5. 
Depicts Mean (± SEM) responses/session on the EtOH lever in female P rats (n = 5–6/
group) given 0, 1, 10, or 30 μg/kg CP 55,940 15 min prior to the initial 4 ADE sessions. * 
Indicates that vehicle, 1 or 10 μg/kg groups responded more compared to baseline levels, 30 
μg/kg group responded less compared to baseline, and all groups were different from each 
other. + Indicates that 1 or 10 μg/kg groups responded more compared to baseline levels, 30 
μg/kg group responded less compared to baseline, and all groups were different from each 
other. # Indicates that 30 μg/kg group responded less compared to baseline levels and were 
different from all other groups.
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